Cingulate CING
NASDAQ CING
$4.55 +0.02 (+0.44%)
As of: Oct 21, 2026 · 10:33 AM EDT

Cingulate (CING) Receivables (2023 - 2024)

Updated

Cingulate (CING) reported Receivables of $2,247 for Q3 2024, down 99.9% from the prior quarter.

Analysis

Cingulate (CING) Receivables (2023 - 2024) Analysis & Trends

At the end of FY2023, Cingulate posted Receivables of $14,622.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,128.06 Bn 1,096.64 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 615.47 Bn 534.00 Bn 17.26 Bn 19.05 Bn
3 AbbVie 504.80 Bn 477.91 Bn 12.70 Bn 13.82 Bn
4 Merck 368.45 Bn 322.83 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.44 Bn 262.43 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.92 Bn 235.60 Bn 12.86 Bn 15.68 Bn
7 Amgen 236.10 Bn 191.50 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 190.71 Bn 164.91 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.16 Bn 116.81 Bn 10.94 Bn 12.49 Bn
10 Cingulate 60.00 Mn 5.00 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 2,247.00
Jun 30, 2024 1.62 Mn
Dec 31, 2023 14,622.00
API Access

Cingulate Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=CING&period=max&api_key=YOUR_API_KEY